LONDON, August 11, 2014 /PRNewswire/ --
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:
InterMune Inc.'s stock edged 0.81% lower on Friday, ending the session at $43.08. A total of 1.93 million shares were traded, near its three months average volume of 2.02 million shares. The stock moved between $42.64 and $43.75 during the session. Shares in InterMune Inc. have gained 2.16% in the last one month and 192.46% from the beginning of 2014. However, the company's shares have lost 3.73% in the previous three trading sessions. The company's stock is trading below its 50-day moving average. The stock's 50-day moving average of $43.50 is above its 200-day moving average of $27.78. Moreover, InterMune Inc.'s stock has a Relative Strength Index (RSI) of 46.61. Sign up and read the free notes on ITMN at:
Shares in Biogen Idec Inc. fluctuated between $319.32 and $326.40 before ending Friday's session 1.08% higher at $324.05. The stock reported a trading volume of 1.20 million shares, which was above its three months average volume of 1.15 million shares. Biogen Idec Inc.'s stock has advanced 1.22% in the last one month and 15.91% on YTD basis, although, the stock has declined 0.36% in the previous three trading sessions. Shares in Biogen Idec Inc. are trading above their 50-day and 200-day moving averages of $319.58 and $300.56, respectively. Further, the company's shares traded at a PE ratio of 35.73 and have an RSI of 50.42. The complimentary notes on BIIB can be downloaded as in PDF format at:
Insmed Inc.'s stock advanced 1.46% on Friday, closing the day at $11.82. The stock recorded a trading volume of 0.72 million shares, which was below its three months average volume of 0.96 million shares. The stock oscillated between $11.55 and $12.35 during the session. Shares in Insmed Inc. have fallen by 7.94% in the previous three trading sessions and 38.05% in the last one month. Moreover, the stock has declined 30.47% since the start of this year. Insmed Inc.'s shares are trading below their 50-day and 200-day moving averages of $16.32 and $16.61, respectively. Additionally, the stock has an RSI of 22.79. Register for free on Investor-Edge and access the latest research on INSM at:
Dendreon Corp.'s stock recorded a trading volume of 1.06 million shares, below its three months average volume of 2.10 million shares. On Friday, the stock finished the day at $2.02, which was 0.50% higher its previous day's closing of $2.01, and registered an intraday range of $1.97 and $2.05. Shares in Dendreon Corp. have lost 0.98% in the previous three trading sessions and 11.01% in the last one month. Additionally, the company's shares are down 32.44% on YTD basis. Shares in Dendreon Corp. are trading below their 50-day and 200-day moving averages of $2.13 and $2.63, respectively. Furthermore, the stock has an RSI of 37.98. The complete research on DNDN is available for free at:
Shares in Alexion Pharmaceuticals Inc. gained 2.02% on Friday, closing the session at $159.11. A total of 0.68 million shares were traded, which was below its three months average volume of 1.18 million shares. The stock moved between $155.55 and $159.60 during the session. Shares of the company traded at a PE ratio of 74.02. Alexion Pharmaceuticals Inc.'s stock has advanced 1.69% in the previous three trading sessions and 19.74% from the beginning of 2014, although, the stock has fallen by 3.29% in the last one month. The company's stock is trading below its 50-day moving average. The stock's 50-day moving average of $162.84 is above its 200-day moving average of $150.47. Furthermore, Alexion Pharmaceuticals Inc.'s stock has an RSI of 46.68. Free in depth research on ALXN is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.